05/09/2017 - 06:30

PharmAust deal bags 50 anti-cancer patents

05/09/2017 - 06:30


Upgrade your subscription to use this feature.

Perth-listed biotech PharmAust has signed a deal with a leading Japanese chemical company that will give the ASX listed company rights to a library of 50 patents over promising anti-cancer agents. The new patents will complement the development of PharmAust’s main anti-cancer drug Monepantel, which has already shown positive results in fighting cancer.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options